Spatial Transcriptomics Analysis Reveals that CCL17 and CCL22 are Robust Indicators of a Suppressive Immune Environment in Angioimmunoblastic T Cell Lymphoma (AITL)

Front Biosci (Landmark Ed). 2022 Sep 29;27(9):270. doi: 10.31083/j.fbl2709270.

Abstract

Background: T cell lymphoma is a complex and highly aggressive clinicopathological entity with a poor outcome. The angioimmunoblastic T-cell lymphoma (AITL) tumor immune microenvironment is poorly investigated.

Methods: Here, to the best of our knowledge, spatial transcriptomics was applied for the first time to study AITL.

Results: Using this method, we observed that AITL was surrounded by cells bearing immune-suppressive markers. CCL17 and CCL22, the dominant ligands for CCR4, were up-regulated, while the expression of natural killer (NK) cell and CD8+ cytotoxic T lymphocyte (CTL) markers decreased. Colocalization of Treg cells with the CD4+ TFH-GC region was also deduced from the bioinformatic analysis. The results obtained with spatial transcriptomics confirm that AITL has a suppressive immune environment. Chemotherapy based on the CHOP regimen (cyclophosphamide, doxorubicin, vincristine plus prednisone) induced complete remission (CR) in this AITL patient. However, the duration of remission (DoR) remains a concern.

Conclusions: This study demonstrates that AITL has an immune suppressive environment and suggests that anti-CCR4 therapy could be a promising treatment for this lethal disease.

Keywords: AITL; CCL17/CCL22-CCR4 axis; precision medicine; spatial transcriptomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokine CCL17 / genetics
  • Chemokine CCL17 / therapeutic use
  • Chemokine CCL22 / genetics
  • Chemokine CCL22 / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Humans
  • Immunoblastic Lymphadenopathy* / drug therapy
  • Immunoblastic Lymphadenopathy* / genetics
  • Immunoblastic Lymphadenopathy* / pathology
  • Lymphoma, T-Cell* / drug therapy
  • Lymphoma, T-Cell* / genetics
  • Lymphoma, T-Cell* / pathology
  • Prednisone / therapeutic use
  • Transcriptome
  • Tumor Microenvironment / genetics
  • Vincristine / therapeutic use

Substances

  • CCL17 protein, human
  • CCL22 protein, human
  • Chemokine CCL17
  • Chemokine CCL22
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone